Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SGYP 2.72 -0.13 (-4.56%)
price chart
Morning Buzz: iBio (IBIO), Neonode, Inc. (NEON), Synergy Pharmaceuticals ...
Synergy Pharmaceuticals, Inc. (SGYP) are up nearly 8% to $2.95 in early trade in response to a press release from the company that said its Phase 2b study for Plecanatide in patients with irritable bowel syndrome with constipation was positive.
Major Declarations Stocks: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP ...
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) data presented at ACG showed that plecanatide, once-daily oral tablet, significantly better complete spontaneous bowel movement frequency, bowel habits, treatment satisfaction as well as significantly ...
Momentum Stocks in Focus- E Commerce China Dangdang, (NYSE:DANG ...  Techsonian (press release)
Related articles »  
Synergy Pharma presents plecanatide IBS-C clinical trial results
At the American College of Gastroenterology Annual Scientific Meeting, Synergy Pharmaceuticals (SGYP +6.6%) presented data from a 423-patient Phase 2b dose-ranging study assessing the safety and efficacy of plecanatide in patients with irritable bowel ...
Synergy Pharma (SGYP) Presents Statistically Significant Plecanatide Phase ...  StreetInsider.com (subscription)
Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for ...  Finances.com
Related articles »  
News Review: DryShips, Inc. (NASDAQ:DRYS), Synergy Pharmaceuticals Inc ...
Lakeway, NY - (MARKET NEWS CALL) - 10/21/2014� Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S.
Related articles »  
Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC).
Related articles »  
Traders Watch list -Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pixelworks ...
Las Vegas, NV �October15, 2014� (TechSonian) �Synergy Pharmaceuticals Inc(NASDAQ:SGYP)declared that it will present additional positive data from a phase 2b study assessing plecanatide's efficacy and safety in patients with irritable bowel syndrome ...
Stocks on the Move � Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Mack Cali ...
Synergy Pharmaceuticals Inc (SGYP) a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases.
Related articles »  
Synergy Pharmaceuticals to Present Additional Positive Phase 2b Study Results ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it will present additional positive data from a phase 2b study assessing plecanatide's efficacy and safety in patients with irritable bowel syndrome with ...
Related articles »  
Synergy Pharmaceuticals Reaches New 1-Year Low at $2.61 (SGYP)
Synergy Pharmaceuticals logo Synergy Pharmaceuticals (NASDAQ:SGYP) hit a new 52-week low during trading on Wednesday , Stock Ratings Network reports.
Related articles »  
Intraday Movers:Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Unilever N.V. ...
Manhattan, NY- SEP 26, 2014 - (Techsonian) �Synergy Pharmaceuticals Inc (NASDAQ:SGYP)declared that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation ...
Synergy Pharmaceuticals Reaches New 1-Year Low at $2.84 (SGYP)  Intercooler
Related articles »